• Kura Oncology highlighted KOMZIFTI (ziftomenib) FDA clearance for adult relapsed or refractory NPM1-mutated AML.
• Reported early launch momentum, with plans to expand ziftomenib use toward up to 50% of AML patients.
• Ziftomenib 600 mg with venetoclax/azacitidine in relapsed or refractory NPM1-mutated AML showed ORR 87% in venetoclax-naïve patients.
• Venetoclax-experienced patients showed ORR 48%; median overall survival 7.4 months; median CRc duration of response 8.6 months.
• Cash and investments totaled USD 580.8 million as of 3/31/26; additional USD 180 million in anticipated payments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.